参芎葡萄糖注射液联合托拉塞米治疗心力衰竭的疗效及对血液流变学指标、hs-CRP和NT-proBNP水平的影响

Therapeutic effect of Shenxiong glucose injection combined with Tora Semide on heart failure and its effect on the level of NT-proBNP, hs-CRP and hemorheological indexes

  • 摘要: 目的 研究参芎葡萄糖注射液联合托拉塞米治疗心力衰竭的疗效及对血液流变学指标、高敏C反应蛋白(highsensitivity C-reactive protein,hs-CRP)和N末端脑钠肽前体(N-terminal-pro-brain-natriuretic-peptide,NT-proBNP)水平的影响。 方法 选取我院2017年10月- 2018年4月收治的心力衰竭患者80例,使用随机数字表法分为治疗组(40例)及对照组(40例)。两组均给予常规强心、扩张血管、血管紧张素转换酶抑制剂(angiotensin converting enzyme inhibitor,ACEI)、β受体阻滞剂和醛固酮受体拮抗剂等治疗,对照组在此基础上给予托拉塞米进行治疗,治疗组给予托拉塞米+静脉滴注参芎葡萄糖注射液治疗。治疗4周后观察两组疗效,对比两组治疗前后血液流变学指标、hs-CRP和NT-proBNP水平、心功能指标以及不良反应的发生情况。 结果 治疗后,观察组治疗总有效率92.50%(37/40)高于对照组75.00%(30/40)(P< 0.05)。治疗后观察组的红细胞压积(hematokrit,HCT)(24.54±2.88)% vs (32.47±4.47)%、红细胞电泳时间(erythrocyte electrophoresis,EEP)(298.47±13.56) s vs (327.45±14.29) s、红细胞沉降率 (erythrocyte sedimentation rate,ESR)(18.66±4.85) mm/h vs (22.71±3.57) mm/h及血浆黏度(plasma viscosity,PV)(1.19±0.37) mPa/s vs (1.76±0.27) mPa/s均明显低于对照组,差异有统计学意义(P均< 0.05);血浆的hs-CRP及NT-proBNP水平均显著低于对照组(P< 0.01);观察组6 min步行距离及左心室射血分数(left ventricular ejection fractions,LVEF)均显著高于对照组(P< 0.01);不良反应发生率两组无统计学差异(P> 0.05)。 结论 参芎葡萄糖注射液联合托拉塞米治疗心力衰竭能提升治疗效果,改善患者血液流变学指标及心功能指标,安全可靠。

     

    Abstract: Objective To study the effect of Shenxiong glucose injection combined with Tora Semide in the treatment of heart failure and its effect on hemorheology, the level of N-terminal-pro-brain-natriuretic-peptide (NT-proBNP) and high-sensitivity C-reactive protein (hs-crp). Methods Eighty patients were selected in our hospital from October 2017 to April 2018, and they were randomly divided into the treatment group (n=40) and the control group (n=40). Angiotensin converting enzyme inhibitor(ACEI), cardiotonic drugs, vasodilator, beta blocker, aldosterone receptor antagonist and other treatment were given to both two groups. On this basis, torasemide treatment was given to the control group, and the treatment group received intravenous infusion of Shenxiong glucose injection plus former treatment. After 4 weeks of treatment, the therapeutic effects of two groups were observed.The changes of hemorheology, hs-CRP and NT-proBNP levels and cardiac function in two groups before and after treatment and the incidence of adverse reactions in two groups during treatment were compared. Results After treatment, the total effective rate of the observation group was 92.50% (37/40), which was significantly higher than that of the control group (75.00%, 30/40) (P< 0.05).After treatment, the HCT, EEP, ESR and PV in the observation group were significantly lower than those in the control group HCT:24.54%±2.88% vs 32.47%±4.47%, EEP: (298.47±13.56) s vs (327.45±14.29) s, ESR: (18.66±4.85) mm/h vs (22.71±3.57) mm/h, PV: (1.19±0.37) mPa/s vs (1.76±0.27) mPa/s, all P< 0.05. The plasma hs-CRP and NT-proBNP levels in the observation group were significantly lower than those in the control group (P< 0.01), while the 6-min walking distance and LVEF in observation group were significantly higher than control group (P< 0.01). There was no significant difference in adverse reaction rate between two groups (P> 0.05). Conclusion Shenxiong glucose injection combined with torasemide can be used in treatment of heart failure by improving the hemorheological index and cardiac function index, which is safe and reliable.

     

/

返回文章
返回